The CDC made this recommendation after reviewing relevant literature and noting that complete testing jumped from about only two-thirds of patients to nearly all patients.
This article was originally published on Contagion Live. It has been lightly edited.
The CDC has recommended more complete one-step hepatitis C testing. This testing will increase the percentage of patients with hepatitis C who are linked to care and receive antiviral therapy, according to the CDC’s Morbidity and Mortality Weekly.
The current CDC testing guidelines include a 2-step process, but the authors noted that about one-third of patients receive incomplete testing, leading to a gap between those who have hepatitis C and those who undergo testing for infection detection.
The former process was developed in 2013 and was made up of 4 possible operational strategies (“steps”) used to diagnose hepatitis C infection:
Steps 2 through 4 allow for single-visit sample collection, the authors noted, which means there is no required second health care visit. Using step 1 requires 2 health care facility visits, “and therefore leads to missed opportunities for HCV diagnosis and linkage to curative HCV treatment,” the authors commented.
In October 2021, leaders in hepatitis C from around the US convened at a meeting to discuss obstacles in testing. Then, the CDC reviewed published literature to make a determination about the magnitude of incomplete hepatitis C testing and its consequences.
The CDC found that, for example, only 66% of hepatitis C antibody reactive patients who reported to the New York City Department of Health and Mental Hygiene surveillance system had complete hepatitis C testing. This resulted in a requirement instituted in 2015 that all labs perform automatic hepatitis C RNA testing (steps 2-4), the authors noted.
Only two-thirds of patients among Veterans Health Administration (VA) facilities came back for their second visit, they said. But when only using steps 2-4, the VA patients who had complete testing rose to 98%.
A similar increase was found among Cherokee Nation Health Services data. About two-thirds of persons had complete hepatitis C testing when using step 1, but after implementing using just steps 2 through 4, the proportion with complete testing rose to 85%, the authors said.
The CDC further added that step 1 has not been found to be cost-effective, either.
When considering all the evidence, the CDC issued a directive that step 1 should be discontinued, while steps 2, 3 and 4 should be used to diagnose current hepatitis C infection. Sites performing hepatitis C screening should ensure that single-visit sample collections are used to avoid incomplete testing, they further noted.
“Using a single visit to conduct both steps of the HCV testing sequence will increase complete diagnosis of current HCV infection, which will increase the percentage of patients with current HCV infection who are linked to care and receive curative antiviral therapy,” the authors concluded.
Reference
Cartwright EJ, Patel P, Kamili S, Wester C. Updated operational guidance for implementing CDC’s recommendations on testing for hepatitis C virus infection. MMWR Morb Mortal Wkly Rep 2023;72:766-768. doi:10.15585/mmwr.mm7228a2
Managed Care Reflections: A Q&A With Charles N. (Chip) Kahn III, MPH
July 30th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The August issue features a conversation with Charles N. (Chip) Kahn III, MPH, the president and CEO of the Federation of American Hospitals and a longtime member of the AJMC editorial board.
Read More
FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older
July 29th 2025The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen